Skip to content
DataLookout
Menu

NCT04178005

Cladribine Tablets After Treatment With Natalizumab (CLADRINA)

StatusActive, Not Recruiting
PhasePhase 4
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 14 versions: 11 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Aug 30, 2026 to May 30, 2027 Show 4 more changesShow less
    • Eligibility criteria expanded, about 29 words
    • Study completion pushed from Dec 2026 to Aug 2027
    • Secondary endpoints: details revised at 1 of 1 entry
    • Publications: details revised at 36 of 39 entries
  2. Notable Primary completion date: Aug 30, 2024 to Aug 30, 2026v12
  3. Minor Study sites: 1 to 2v11
  4. Minor Study completion date: Dec 2024 to Dec 2026
    • Study description expanded, about 59 words
    v10
  5. Notable Primary completion date: Aug 30, 2022 to Aug 30, 2024
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v9
Show 5 earlier versionsHide 5 earlier versions
  1. Minor Primary completion date: Jul 1, 2022 to Aug 30, 2022v8
  2. Minor Primary completion date: Mar 2022 to Jul 1, 2022
    • Study completion date: Dec 2022 to Dec 2024
    v7
  3. Notable Eligibility criteria expanded, about 2 wordsv6
  4. Notable Trial status: Not Yet Recruiting to Recruiting
    • Eligibility criteria shortened, about 7 words
    • Start date changed from estimate of Mar 2020 to Feb 19, 2020
    • Site details revised
    v5
  5. Notable Eligibility criteria expanded, about 14 wordsv3 Show 4 more changesShow less
    • Primary endpoint revised
    • Secondary endpoints: 2 to 1
    • Study description shortened, about 365 words
    • Publications: details revised at 39 of 39 entries
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Absolute and percent change of T cells, B cells, DC subset and NfL levels in blood.
Timeframe: 24 months

Secondary (1)

Annualized Relapse Rate (ARR)

Arms and interventions

CladribineOther

All study participants will receive treatment with cladribine 10 mg tablets at the recommended cumulative dose of 3.5 mg/kg, divided into 2 yearly treatment courses (1.75 mg/kg per treatment course). This regimen corresponds to the recommended dosage as per the USPI. Each treatment course is divided into 2 treatment cycles: * Administration of first treatment course (year 1 treatment): * First cycle: Starts on Day 1 of the study * Second cycle: Administered 23 to 27 days after the last dose of first cycle. * Administration of second treatment course (year 2 treatment): * First cycle: Administered at least 43 weeks after the last dose of year 1 treatment * Second cycle: Administered 23 to 27 days after the last dose of first cycle of year 2 treatment. The cycle dosage will be administered as 1 or 2 cladribine 10 mg tablets daily over 4 or 5 consecutive days.

Drugs: Cladribine

Sites

2 sites in 1 country